abstract |
The present invention relates to the novel use of EDG2 inhibitors for treating rheumatoid arthritis, particularly in those patients exhibiting elevated levels of pro-inflammatory molecules despite having been treated with anti-inflammatories, i.e. patients not responding to said treatments. |